

REMARKS

In response to the action dated May 9, 2005 and the Advisory Action dated August 18, 2005, please enter the earlier-filed terminal disclaimer, amend the specification, amend claims 4 and 6, and cancel claims 5 to 10 and 12. Applicants respectfully request reconsideration in view of the terminal disclaimer, the amendments and the following remarks.

Applicants have amended paragraph 31 and claims 4 and 6 to remove the term imidazole from the list of preferred hydrazine derivatives. Hydrazine derivatives have a double nitrogen (N-N) structure and imidazole has a nitrogen-carbon-nitrogen (N-C-N) structure. Upon closer review of the specification and claims, Applicants have realized that imidazole has an incorrect structure for inclusion as a hydrazine derivative. Thus, Applicants have removed this compound from the list of paragraph 31 and claims 4 and 6 to correct the error. Applicants respectfully submit that these amendments enter no new matter.

In response to the Examiner's request Applicants have cancelled claims 5 to 10 and 12. But because claim 1 represents a generic claim that includes claims 5 to 8 and 12 and the method claims (9 and 10) also include the compositional limitations, Applicants respectfully request reconsideration of the restriction requirement upon allowance of claim 1.

The action rejects claims 1 to 4 and 11 for obviousness-type double patenting in view of US. Pat. Pub. No. 2005/0031789 (Liu et al.) in different combinations in a total of three separate rejections. Applicants respectfully submit that these rejections become moot in view of the earlier-filed terminal disclaimer.


The action rejects claims 1 to 4 as being obvious in view of EP 1229093 ('093). Specifically EP '093 discloses hydrogen peroxide, an abrasive, an organic ammonium salt and

imidazole. Imine (C=NH) and imine derivatives require a bivalent radical with a carbon to nitrogen double bond. Since imidazole is a tautomer that shares an active hydrogen atom between two nitrogen atoms, it lacks the bivalent radical and is not an imine derivative. Furthermore, imidazole (N-C-N structure) is not a hydrazine derivative because it lacks a double nitrogen (N-N) structure. Thus, since the '093 patent does not disclose the use of an imine derivative or hydrazine derivative for facilitating barrier removal, Applicants respectfully submit that EP '093 does not disclose or suggest the claimed invention.

Applicants respectfully request reconsideration of the amended claims. If a telephone call would expedite matters, then please call me at 302-283-2136.

Respectfully submitted,

Sept 2nd, 2005
Date



Blake T. Biederman
Attorney for Applicant(s)
Reg. No. 34,124

Blake T. Biederman
Patent Attorney
1105 North Market Street
Suite 1300
Wilmington, DE 19899
Tel. 302-283-2136